See the DrugPatentWatch profile for albumin

Albumin binding plays a significant role in affecting the solubility of paclitaxel, an anticancer drug used to treat a variety of cancers including ovarian, breast, and non-small cell lung cancer [1]. Paclitaxel is a hydrophobic drug, which means it is not soluble in water, making it challenging to administer [1].

Albumin, a protein found in blood plasma, can bind to paclitaxel and increase its solubility, allowing for improved drug delivery [1]. The binding of paclitaxel to albumin forms a drug-protein complex, which enhances the drug's solubility and stability, thereby facilitating its administration [1].

The albumin-bound paclitaxel formulation is known as Abraxane, which was approved by the FDA in 2005 [1]. Abraxane has several advantages over the traditional paclitaxel formulation, including improved solubility, higher maximum tolerated dose, and reduced side effects such as hypersensitivity reactions and neurotoxicity [1].

In summary, albumin binding plays a crucial role in enhancing the solubility of paclitaxel, enabling improved drug delivery and therapeutic outcomes.

Sources:

[1] DrugPatentWatch.com. (n.d.). Paclitaxel. Retrieved from <https://www.drugpatentwatch.com/drugs/paclitaxel>